A5068115190- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Cholinesterase and Neurodegenerative Diseases
- Balance, Gait, and Falls Prevention
- Functional Brain Connectivity Studies
- Botulinum Toxin and Related Neurological Disorders
- Alzheimer's disease research and treatments
- Nicotinic Acetylcholine Receptors Study
- Neuroscience and Neuropharmacology Research
- Cerebral Palsy and Movement Disorders
- Olfactory and Sensory Function Studies
- Motor Control and Adaptation
- Dementia and Cognitive Impairment Research
- Autism Spectrum Disorder Research
- Computational Drug Discovery Methods
- Biochemical Analysis and Sensing Techniques
- Neuroscience and Neural Engineering
- Memory and Neural Mechanisms
- Advanced Neuroimaging Techniques and Applications
- Neurological Disease Mechanisms and Treatments
- Vestibular and auditory disorders
- Advanced Chemical Sensor Technologies
- Neurotransmitter Receptor Influence on Behavior
- Attention Deficit Hyperactivity Disorder
- Ginkgo biloba and Cashew Applications
Critical Path Institute
2021-2025
University of Michigan
2014-2023
Parkinson's Foundation
2020-2022
Michigan United
2012-2021
VA Ann Arbor Healthcare System
2009-2020
Geriatric Research Education and Clinical Center
2009-2020
Michigan Medicine
2020
China-Japan Friendship Hospital
2019
University of North Carolina at Chapel Hill
2019
Ann Arbor Center for Independent Living
2015-2018
<b>Objective:</b> To investigate the relationships between history of falls and cholinergic vs dopaminergic denervation in patients with Parkinson disease (PD). <b>Background:</b> There is a need to explore nondopaminergic mechanisms gait control as majority motor impairments associated PD are resistant treatment. Alterations neurotransmission may be implicated because evidence that depends on system–mediated higher-level cortical subcortical processing, including pedunculopontine nucleus...
Olfactory dysfunction is common in subjects with Parkinson’s disease. The pathophysiology of such dysfunction, however, remains poorly understood. Neurodegeneration within central regions involved odour perception may contribute to olfactory Central cholinergic deficits occur disease and neurons innervate regions, as the limbic archicortex, perception. We investigated relationship between performance on an identification task forebrain denervation without dementia. Fifty-eight patients (mean...
Rapid eye movement sleep behavior disorder (RBD) is common in Parkinson disease (PD), but its relationship to the varied neurotransmitter deficits of PD and prognostic significance remain incompletely understood. RBD cholinergic system degeneration are identified independently as risk factors for cognitive impairment PD. We aimed assess association between denervation symptoms patients without dementia.Eighty subjects with dementia (age, 64.6 ± 7.0 years; range, 50-82 60 males, 20 females;...
In this study, we apply a multidisciplinary approach to investigate falls in PD patients using clinical, demographic and neuroimaging data from two independent initiatives (University of Michigan Tel Aviv Sourasky Medical Center). Using machine learning techniques, construct predictive models discriminate fallers non-fallers. Through controlled feature selection, identified the most salient predictors patient including gait speed, Hoehn Yahr stage, postural instability difficulty-related...
Objective Postural instability and gait difficulties (PIGDs) represent debilitating disturbances in Parkinson's disease (PD). Past acetylcholinesterase positron emission tomography (PET) imaging studies implicate cholinergic changes as significant contributors to PIGD features. These were limited quantification of striatal synapse integrity. Vesicular acetylcholine transporter (VAChT) PET ligands are better suited for evaluation high binding areas. We examined associations between regional...
We investigated dopaminergic and cholinergic correlates of gait speed in Parkinson disease (PD) non-PD control subjects to test the hypothesis that dysfunction PD may result from multisystem degeneration.This was a cross-sectional study. Subjects with but without dementia (n = 125, age 65.6 ± 7.3 years) elderly 32, 66.0 10.6 underwent [¹¹C]dihydrotetrabenazine [(11)C]methyl-4-piperidinyl propionate acetylcholinesterase PET imaging, cognitive clinical testing, including an 8.5-m walk "off"...
Parkinson's disease (PD) is a progressive neurodegenerative disorder that characterized by dopamine depletion in the striatum. One consistent pathophysiological hallmark of PD an increase spontaneous oscillatory activity basal ganglia thalamocortical networks. We evaluated these effects using resting state functional connectivity MRI (fcMRI) mild to moderate stage patients on and off L-DOPA age-matched controls six different striatal seed regions. observed overall strength cortico-striatal...
Parkinson's disease (PD) is a multisystem neurodegenerative disorder. Heterogeneous clinical features may reflect heterogeneous changes in different brain regions. In contrast to the pronounced nigrostriatal denervation characteristic of PD, cholinergic are less marked. We investigated innervation activity PD subjects relative normal subjects. Nondemented ( n=101, age 65.3±7.2 years) and n=29, 66.8±10.9 underwent assessment [ 11 C]methyl-4-piperidinyl propionate acetylcholinesterase...
The pathophysiology of postural instability in Parkinson's disease remains poorly understood. Normal function depends part on the ability control system to integrate visual, proprioceptive, and vestibular sensory information. Degeneration cholinergic neurons brainstem pedunculopontine nucleus complex their thalamic efferent terminals has been implicated deficits disease. Our aim was investigate relationship terminal loss thalamus cortex, nigrostriatal dopaminergic denervation, integration We...
Little is known about the relative contributions of multisystem degenerative processes across spectrum predemented cognitive decline in Parkinson disease (PD).To investigate frequency caudate nucleus dopaminergic and forebrain cholinergic deficits a cognitively impaired patients with PD to explore their relative, individual, combined impairment PD.A cross-sectional study at an academic movement disorders clinic that included predominantly nondemented cohort 143 PD. The mean (SD) age was 65.5...
(–)-5-<sup>18</sup>F-fluoroethoxybenzovesamicol (<sup>18</sup>F-FEOBV) is a vesamicol derivative that binds selectively to the vesicular acetylcholine transporter (VAChT) and has been used in preclinical studies quantify presynaptic cholinergic nerve terminals. This study presents, our knowledge, first-in-human experience with <sup>18</sup>F-FEOBV, including radiation dosimetry, biodistribution, tolerability safety human subjects, brain kinetics methods for quantitative analysis of...
Cholinergic denervation has been associated with falls and slower gait speed β-amyloid deposition greater severity of axial motor impairments in Parkinson disease (PD). However, little is known about the association between presence extra-nigral pathological conditions freezing (FoG). Patients PD (n = 143; age, 65.5 ± 7.4 years, Hoehn Yahr stage, 2.4 0.6; Montreal Cognitive Assessment score, 25.9 2.6) underwent [(11) C]methyl-4-piperidinyl propionate acetylcholinesterase...
There is a critical need to develop valid, non-invasive biomarkers for Parkinsonian syndromes. The current 17-site, international study assesses whether diffusion MRI (dMRI) can distinguish between
ABSTRACT Background The cholinergic system plays a key role in cognitive impairment Parkinson's disease (PD). Previous acetylcholinesterase positron emission tomography imaging studies found memory, attention, and executive function correlates of global cortical losses. Vesicular acetylcholine transporter allows for more accurate topographic assessment not only but also subcortical changes. Objective objectiveof this study was to investigate the relationship between functioning regional...
Abstract Background Altered cholinergic innervation plays a putative role in cognitive impairment Parkinson's disease (PD) at least advanced stages. Identification of the relationship between and early will provide better insight into prognosis possible intervention. Objective The aim was to assess regional status de novo patients with PD, without impairment. Methods Fifty‐seven newly diagnosed, treatment‐naive, PD (32 men, mean age 64.6 ± 8.2 years) 10 healthy controls (5 54.6 6.0 were...
Patient perspectives on meaningful symptoms and impacts in early Parkinson's disease (PD) are lacking urgently needed to clarify priority areas for monitoring, management, new therapies.
Digital measures may provide objective, sensitive, real-world of disease progression in Parkinson's (PD). However, multicenter longitudinal assessments such are few. We recently demonstrated that baseline gait, tremor, finger tapping, and speech from a commercially available smartwatch, smartphone, research-grade wearable sensors differed significantly between 82 individuals with early, untreated PD 50 age-matched controls. Here, we evaluated the change these over 12 months observational...
Leucoaraiosis is associated with motor symptoms in otherwise normal older adults. Comorbid leucoaraiosis predicted to contribute also features Parkinson's disease but previous studies of white matter changes show variable results. No prior have compared directly the effects both and degree nigrostriatal dopaminergic denervation on features. We investigated effect severity impairment independent disease. Seventy-three subjects (Hoehn Yahr stages 1-3) underwent brain magnetic resonance...
The aim of our study was to examine the relationship between corticostriatal Aβ-amyloid deposition and cognitive dysfunction in a cohort patients with Parkinson disease (PD) at risk for dementia.This cross-sectional 40 PD mild impairment (MCI) or other known dementia factors. Subjects underwent dynamic vesicular monoamine transporter 2 PET imaging using [(11)C] Pittsburgh compound B (PiB) [(11)C]dihydrotetrabenazine (DTBZ), respectively, neuropsychological assessment. PiB DTBZ data were...
Insomnia and daytime sleepiness are common complaints in Parkinson disease (PD), but the main causes remain unclear. We examined potential impact of both motor non-motor symptoms PD on sleep problems.Patients with (n = 128) were assessed using Severity Index, Epworth Sleepiness Scale, Unified Disease Rating Beck Depression Inventory, Fatigue Survey Autonomic Symptoms, 39-item Questionnaire. A subset subjects 38, 30%) also completed nocturnal polysomnography a multiple latency test...